Silvant Capital Management LLC Makes New Investment in Insulet Corporation $PODD

Silvant Capital Management LLC bought a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,619 shares of the medical instruments supplier’s stock, valued at approximately $703,000.

Other institutional investors also recently bought and sold shares of the company. Larson Financial Group LLC lifted its holdings in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new position in Insulet during the 4th quarter worth $26,000. Elyxium Wealth LLC acquired a new position in Insulet during the 4th quarter valued at about $28,000. DV Equities LLC purchased a new stake in Insulet in the fourth quarter valued at about $28,000. Finally, MV Capital Management Inc. purchased a new stake in Insulet in the fourth quarter valued at about $29,000.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Negative Sentiment: Multiple law firms announced or promoted a securities class action against Insulet and certain executives. The complaints allege that the company made materially false or misleading statements about manufacturing controls, product quality, and the safety and reliability of Omnipod devices. The allegations have not been proven in court. Pomerantz class action announcement
• Negative Sentiment: The investor notices link the case to two Omnipod medical-device corrections and claim that related disclosures contributed to a substantial decline in Insulet’s stock. One notice cited a move from $236.07 to $146.01 across the alleged corrective disclosures, or losses exceeding $90 per share for some investors. SueWallSt investor notice
• Negative Sentiment: The legal overhang intensified as several firms—including Robbins Geller, Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, Bernstein Liebhard, Glancy Prongay, Robbins LLP, Levi & Korsinsky, and Portnoy—urged affected shareholders to seek lead-plaintiff status or evaluate potential recovery. The deadline to move for lead-plaintiff appointment is August 31, 2026. Robbins Geller deadline announcement

Insulet Trading Down 3.1%

Insulet stock opened at $146.87 on Friday. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a market capitalization of $10.19 billion, a price-to-earnings ratio of 27.45, a price-to-earnings-growth ratio of 1.19 and a beta of 1.10. The stock has a 50-day moving average price of $154.70 and a 200 day moving average price of $185.07.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same quarter in the prior year, the company earned $1.17 EPS. Insulet’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Sell-side analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on PODD. Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 price target (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. UBS Group decreased their price objective on shares of Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research report on Thursday, August 6th. Bank of America lowered their target price on shares of Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Raymond James Financial restated an “outperform” rating and set a $180.00 price target on shares of Insulet in a research note on Thursday, August 6th. Finally, Evercore set a $180.00 price target on shares of Insulet in a report on Monday, July 6th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Insulet presently has an average rating of “Hold” and an average target price of $195.40.

Insiders Place Their Bets

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of Insulet stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.36% of the company’s stock.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.